Skip Navigation



Journal of the National Cancer Institute Advance Access published online on August 28, 2007
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djm148
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/17/1284    most recent
djm148v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

ARRESTED DEVELOPMENT?

Notch Emerges as New Cancer Drug Target

Ken Garber

The first 150 words of the full text of this article appear below.

A metaphor for cancer is normal development gone awry. All tissues in the body arise from embryonic stem cells that gradually give rise to specialized cells. Cancer resembles a case of arrested development because less differentiated tumors are almost always the most aggressive. So it's no surprise that genes regulating normal fetal and childhood development have been implicated in adult cancer. The question now: If a gene regulating development can cause cancer, can blocking that gene eradicate the tumor?

One such gene is Notch. First described almost a century ago, Notch has become the object of intense study in cancer. Evidence is growing that Notch signaling can drive the growth of a wide range of tumors, from leukemia to breast cancer. At least two cancer clinical trials are under way using Notch inhibitors, and several others are pending. "This is an exploding field," says Lucio Miele, M.D., Ph.D., a cancer . . . [Full Text of this Article]

Keeping Stem Cells Alive

Targeting Notch: Risks and Rewards


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways
Gillian Farnie, Robert B. Clarke, Katherine Spence, Natasha Pinnock, Keith Brennan, Neil G. Anderson, and Nigel J. Bundred
J Natl Cancer Inst 2007 99: 616-627. [Abstract] [Full Text] [PDF]

Targeting Vessel Abnormalization in Cancer
Ken Garber
J Natl Cancer Inst 2007 99: 991-995. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
D. M. Simeone
Pancreatic Cancer Stem Cells: Implications for the Treatment of Pancreatic Cancer
Clin. Cancer Res., September 15, 2008; 14(18): 5646 - 5648.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. R. Mertens, U. Raffetseder, and T. Rauen
Notch receptors: a new target in glomerular diseases
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2743 - 2745.
[Full Text] [PDF]